Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic

J-J Tuech, A Gangloff, F Di Fiore, P Michel, C Brigand, K Slim, M Pocard, L Schwarz, J-J Tuech, A Gangloff, F Di Fiore, P Michel, C Brigand, K Slim, M Pocard, L Schwarz

Abstract

The Covid-19 pandemic is changing the organization of healthcare and has a direct impact on digestive surgery. Healthcare priorities and circuits are being modified. Emergency surgery is still a priority. Functional surgery is to be deferred. Laparoscopic surgery must follow strict rules so as not to expose healthcare professionals (HCPs) to added risk. The question looms large in cancer surgery-go ahead or defer? There is probably an added risk due to the pandemic that must be balanced against the risk incurred by deferring surgery. For each type of cancer-colon, pancreas, oesogastric, hepatocellular carcinoma-morbidity and mortality rates are stated and compared with the oncological risk incurred by deferring surgery and/or the tumour doubling time. Strategies can be proposed based on this comparison. For colonic cancers T1-2, N0, it is advisable to defer surgery. For advanced colonic lesions, it seems judicious to undertake neoadjuvant chemotherapy and then wait. For rectal cancers T3-4 and/or N+, chemoradiotherapy is indicated, short radiotherapy must be discussed (followed by a waiting period) to reduce time of exposure in the hospital and to prevent infections. Most complex surgery with high morbidity and mortality-oesogastric, hepatic or pancreatic-is most often best deferred.

Keywords: Cancer; Coronavirus; Covid-19; Digestive surgery; Surgical complications.

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

References

    1. Liang W., Guan W., Chen R. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337.
    1. Zhang Y., Xu J.M. [Medical diagnosis and treatment strategies for malignant tumors of the digestive system during the outbreak of novel coronavirus pneumonia] Zhonghua Zhong Liu Za Zhi. 2020;42(0):E005.
    1. Chen Y.H., Peng J.S. [Treatment strategy for gastrointestinal tumor under the outbreak of novel coronavirus pneumonia in China] Zhonghua Wei Chang Wai Ke Za Zhi. 2020;23(2):I–IV.
    1. Hu X.H., Niu W.B., Zhang J.F. [Thinking of treatment strategies for colorectal cancer patients in tumor hospitals under the background of coronavirus pneumonia] Zhonghua Wei Chang Wai Ke Za Zhi. 2020;23(3):E002.
    1. Wu F., Song Y., Zeng H.Y. [Discussion on diagnosis and treatment of hepatobiliary malignancies during the outbreak of novel coronavirus pneumonia] Zhonghua Zhong Liu Za Zhi. 2020;42(0):E004.
    1. Alves A., Panis Y., Mathieu P. Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg. 2005;140(3):278–283. [discussion 84]
    1. Denost Q., Rouanet P., Faucheron J.L. To Drain or Not to Drain Infraperitoneal Anastomosis After Rectal Excision for Cancer: The GRECCAR 5 Randomized Trial. Ann Surg. 2017;265(3):474–480.
    1. Lefevre J.H., Mineur L., Kotti S. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Chemoradiotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized Controlled Trial (GRECCAR-6) J Clin Oncol. 2016;34(31):3773–3780.
    1. Habr-Gama A., Perez R.O., Sabbaga J., Nadalin W., Sao Juliao G.P., Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum. 2009;52(12):1927–1934.
    1. El Amrani M., Lenne X., Clement G. Specificity of Procedure volume and its Association With Postoperative Mortality in Digestive Cancer Surgery: A Nationwide Study of 225,752 Patients. Ann Surg. 2019;270(5):775–782.
    1. Schwarz L., Bruno M., Parker N.H. Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy. Ann Surg Oncol. 2015;22(11):3522–3529.
    1. Mirkin K.A., Hollenbeak C.S., Wong J. Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer. J Gastrointest Surg. 2018;22(8):1365–1375.
    1. Swords D.S., Zhang C., Presson A.P., Firpo M.A., Mulvihill S.J., Scaife C.L. Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery. Surgery. 2018;163(4):753–760.
    1. Mariette C., Markar S., Dabakuyo-Yonli T.S. Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open Esophagectomy for Patients With Esophageal Cancer, Analysis of a Multicenter, Open-label. Randomized Phase III Controlled Trial: The MIRO Trial. Ann Surg. 2019
    1. Bartlett E.K., Roses R.E., Kelz R.R., Drebin J.A., Fraker D.L., Karakousis G.C. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. Surgery. 2014;156(2):298–304.
    1. Wang W.J., Li R., Guo C.A. Systematic assessment of complications after robotic-assisted total versus distal gastrectomy for advanced gastric cancer: A retrospective propensity score-matched study using Clavien-Dindo classification. Int J Surg. 2019;71:140–148.
    1. Fujiya K., Irino T., Furukawa K. Safety of prolonged wait time for gastrectomy in clinical stage I gastric cancer. Eur J Surg Oncol. 2019;45(10):1964–1968.
    1. Oh S.Y., Lee J.H., Lee H.J. Natural History of Gastric Cancer: Observational Study of Gastric Cancer Patients Not Treated During Follow-Up. Ann Surg Oncol. 2019;26(9):2905–2911.
    1. Kawaguchi Y., Fuks D., Kokudo N., Gayet B. Difficulty of Laparoscopic Liver Resection: Proposal for a New Classification. Ann Surg. 2018;267(1):13–17.
    1. Hobeika C., Fuks D., Cauchy F. Impact of cirrhosis in patients undergoing laparoscopic liver resection in a nationwide multicentre survey. Br J Surg. 2020;107(3):268–277.
    1. An C., Choi Y.A., Choi D. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin Mol Hepatol. 2015;21(3):279–286.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅